475 related articles for article (PubMed ID: 22294718)
1. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Davies BR; Greenwood H; Dudley P; Crafter C; Yu DH; Zhang J; Li J; Gao B; Ji Q; Maynard J; Ricketts SA; Cross D; Cosulich S; Chresta CC; Page K; Yates J; Lane C; Watson R; Luke R; Ogilvie D; Pass M
Mol Cancer Ther; 2012 Apr; 11(4):873-87. PubMed ID: 22294718
[TBL] [Abstract][Full Text] [Related]
2. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
[TBL] [Abstract][Full Text] [Related]
3. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
Li J; Davies BR; Han S; Zhou M; Bai Y; Zhang J; Xu Y; Tang L; Wang H; Liu YJ; Yin X; Ji Q; Yu DH
J Transl Med; 2013 Oct; 11():241. PubMed ID: 24088382
[TBL] [Abstract][Full Text] [Related]
4. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
5. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
Yap TA; Walton MI; Hunter LJ; Valenti M; de Haven Brandon A; Eve PD; Ruddle R; Heaton SP; Henley A; Pickard L; Vijayaraghavan G; Caldwell JJ; Thompson NT; Aherne W; Raynaud FI; Eccles SA; Workman P; Collins I; Garrett MD
Mol Cancer Ther; 2011 Feb; 10(2):360-71. PubMed ID: 21191045
[TBL] [Abstract][Full Text] [Related]
7. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
8. Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363.
Yates JW; Dudley P; Cheng J; D'Cruz C; Davies BR
Cancer Chemother Pharmacol; 2015 Aug; 76(2):343-56. PubMed ID: 26092323
[TBL] [Abstract][Full Text] [Related]
9. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
[TBL] [Abstract][Full Text] [Related]
10. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
11. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
[TBL] [Abstract][Full Text] [Related]
12. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V
Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
15. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
Lamoureux F; Thomas C; Crafter C; Kumano M; Zhang F; Davies BR; Gleave ME; Zoubeidi A
Clin Cancer Res; 2013 Feb; 19(4):833-44. PubMed ID: 23258740
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
Addie M; Ballard P; Buttar D; Crafter C; Currie G; Davies BR; Debreczeni J; Dry H; Dudley P; Greenwood R; Johnson PD; Kettle JG; Lane C; Lamont G; Leach A; Luke RW; Morris J; Ogilvie D; Page K; Pass M; Pearson S; Ruston L
J Med Chem; 2013 Mar; 56(5):2059-73. PubMed ID: 23394218
[TBL] [Abstract][Full Text] [Related]
17. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of autophagy and the AKT pathway in prostate cancer.
Lamoureux F; Zoubeidi A
Autophagy; 2013 Jul; 9(7):1119-20. PubMed ID: 23670050
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in
Banerji U; Dean EJ; Pérez-Fidalgo JA; Batist G; Bedard PL; You B; Westin SN; Kabos P; Garrett MD; Tall M; Ambrose H; Barrett JC; Carr TH; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Elvin P; Foxley A; Lawrence P; Lindemann JPO; Maudsley R; Pass M; Rowlands V; Rugman P; Schiavon G; Yates J; Schellens JHM
Clin Cancer Res; 2018 May; 24(9):2050-2059. PubMed ID: 29066505
[No Abstract] [Full Text] [Related]
20. Ceritinib increases sensitivity of AKT inhibitors to gastric cancer.
Wang J; Xu X; Wang T; Guo Q; Dai X; Guo H; Zhang W; Cheng S; Chen X; Ding L
Eur J Pharmacol; 2021 Apr; 896():173879. PubMed ID: 33515539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
